News - Bexsero, Ryzodeg

Filter

Current filters:

BexseroRyzodeg

Popular Filters

Novo Nordisk accused of delaying information release under Danish STC rules

Novo Nordisk accused of delaying information release under Danish STC rules

10-12-2013

Danish insulin giant Novo Nordisk revealed this morning that the Danish Financial Supervisory Authority…

DenmarkDiabetesEuropeFinancialLegalNovo NordiskPharmaceuticalRyzodegTresiba

BNDES invests 804 million real in Novartis' new Brazil biotechnology unit

BNDES invests 804 million real in Novartis' new Brazil biotechnology unit

07-12-2013

The Brazilian Development Bank will finance 804 million real ($342 million) for the construction of a…

BexseroBiotechnologyBrazilFinancialNovartisProductionSouth AmericaVaccines

Novartis MenB vaccine approved in Australia

15-08-2013

Swiss drug major Novartis (NOVN: VX) revealed this morning (August 15) that the Australian Therapeutic…

Asia-PacificBexseroNovartisPharmaceuticalRegulationVaccines

Disappointment for Novartis over rejection of meningitis vaccine in the UK

24-07-2013

The UK Joint Committee on Vaccination and Immunization (JCVI) will not recommend meningitis vaccine Bexsero…

BexseroEuropeHealthcareNovartisPharmaceuticalVaccines

Blow for Novo Nordisk, as FDA further delays Tresiba and Ryzodeg

11-02-2013

Danish insulin giant Novo Nordisk (NOV: N) revealed late Sunday that, on February 8, it received a Complete…

DegludecDiabetesNorth AmericaNovo NordiskPharmaceuticalRegulationRyzodegTresiba

EU approval for Novo Nordisk's Tresiba and Ryzodeg and for Novartis' for Bexsero

22-01-2013

Following positive recommendations from the European Medicines Agency's advisory committee, the European…

BexseroDiabetesEuropeNovartisNovo NordiskPharmaceuticalRegulationRyzodegTresibaVaccines

Novo Nordisk's Ryzodeg passes regulatory hurdle in Japan; diabetes burden review

03-12-2012

Global insulin market leader Novo Nordisk (NOV: N) of Denmark revealed this morning that its Ryzodeg…

Asia-PacificDegludecDiabetesGlobalHealthcareNovo NordiskPharmaceuticalPricingRegulationRyzodegTresiba

Positive CHMP recommendations for Sanofi and Novartis, but not for Celgene

19-11-2012

There was a batch of good news for two pharma companies and a negative opinion for one last Friday coming…

BexseroBiotechnologyCelgeneDiabetesEuropeIstodaxLyxumiaNovartisOncologyPharmaceuticalRegulationSanofiVaccinesZaltrap

FDA accepts Merck & Co's suvorexant; panel backs Novo's Tresiba and Ryzodeg

09-11-2012

US drug giant Merck & Co (NYSE: MRK) says that the New Drug Application for suvorexant, the company's…

DegludecDiabetesMerck & CoNeurologicalNorth AmericaNovo NordiskPharmaceuticalRegulationRyzodegsuvorexantTresiba

FDA briefing papers for Novo Nordisk's insulin degludec note need to review cardiac risks

06-11-2012

The US Food and Drug Administration yesterday published the briefing documents ahead of the Advisory…

DegludecDiabetesNorth AmericaNovo NordiskPharmaceuticalRegulationRyzodegTresiba

Novo Nordisk says US FDA advisory panel to focus on degludec cardiovascular safety

26-10-2012

Denmark-based insulin giant Novo Nordisk (NOV: N) late yesterday announced that the US Food and Drug…

DegludecDiabetesNorth AmericaNovo NordiskPharmaceuticalRegulationRyzodegTresiba

EMA panel backing for Novo Nordisk's Tresiba and Ryzodeg: Japanese review

22-10-2012

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Friday announced…

Asia-PacificDegludecDiabetesEuropeNovo NordiskPharmaceuticalRegulationRyzodegTresiba

FDA further delays Novo Nordisk's ultra long-acting insulin products Tresiba and Ryzodeg

19-07-2012

Denmark's Novo Nordisk (NOV: N), the world's largest insulin maker, says that the US Food and Drug Administration…

DiabetesNorth AmericaNovo NordiskPharmaceuticalRegulationRyzodegTresiba

Novo Nordisk starts year with 15% net profits hike

30-04-2012

Danish insulin giant Novo Nordisk (NOV: N) reported first-quarter 2012 results last Friday, with a 13%…

DegludecDiabetesFinancialNovo NordiskPharmaceuticalRyzodegTresiba

Novartis says Bexsero shows significant potential against meningococcal serogroup B infections

10-06-2011

Swiss drug major Novartis (NVN: VX) says that new data from a pivotal study in more than 1,800 infants…

Antibiotics and Infectious diseasesBexseroNovartisPharmaceuticalResearchVaccines

Back to top